Multi-institutional randomized phase 2 trial of the combination chemotherapy of carboplatin and pemetrexed for advanced nonsquamous non-small-cell lung cancer

Multi-institutional randomized phase 2 trial of the combination chemotherapy of carboplatin and pemetrexed for advanced nonsquamous non-small-cell lung cancer - KCOG-T1112

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008842

Enrollment

Registered

2012-09-03

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonsquamous non-small-cell lung cancer

Interventions

Combination chemotherapy of carboplatin and pemetrexed Single-agent pemetrexed maintenance therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: < First step > 1.Advanced nonsquamous non-small-cell lung cancer 2.ECOG PS0-1 3.Adequate organ function 4.Measurable disese 5.Life expectancy exceeding 3 months 6.Written informed consent < Second step > 1.CR/PR/SD by induction therapy 2.ECOG PS0-1 3.Adequate organ function 4.Measurable disese 5.Life expectancy exceeding 3 months 6.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Squamous cell carcinoma 2.Irradiation for praimary lesion 3.SVC syndrome 4.Uncontrollable pleural effusion 5.Massive ascites or pericardial efusion 6.Interstitial pneumonia revealed by chestXP 7.Symptomatic brain metastasis 8.Untreated double cancer

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
One year survival and safety	—

Countries

Japan

Contacts

Public ContactMasataka Hirabayashi

Hyogo prefectural Amagasaki general medical center Depertment of respiratory medicine

hirabayasi@hp.pref.hyogo.jp09070949480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026